Healthcare Industry News: EpiFix
News Release - November 7, 2014
MiMedx(R) Adds New ExecutiveCHRISTOPHER CASHMAN JOINS MIMEDX AS ITS EXECUTIVE VICE PRESIDENT & CHIEF COMMERCIALIZATION OFFICER
MARIETTA, Ga., Nov. 7, 2014 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Christopher M. Cashman has joined MiMedx as the Company's Executive Vice President & Chief Commercialization Officer.
In his new role, Mr. Cashman will contribute his expertise to the Company's sales & marketing functions, strategic planning and all related revenue growth initiatives. "We are very pleased to have Chris join MiMedx. He is an executive with C-Level experience in both public and private healthcare organizations. Chris has extensive experience in the sales and marketing arena, but he also has excellent operational and general management experience. Beyond sales and marketing, he has expertise in global market commercialization, mergers and acquisitions, intellectual property development, regulatory pathways, and Medicare and commercial reimbursement. We are very fortunate already to have a number of executives within MiMedx that have General Management capabilities, and the addition of Chris will further complement this talent within our organization," said Parker H. "Pete" Petit, Chairman and CEO.
Bill Taylor, President and COO, commented, "Chris is a very seasoned executive and brings over 25 years of experience to MiMedx. He has served in leadership positions in a number of high growth medical organizations. He is extremely knowledgeable and has a track record of success in numerous medical specialty markets including advanced wound care, regenerative medicine, sports medicine, orthopedics, plastic and reconstructive surgery, minimally invasive surgery (MIS) applications and medical devices."
Most recently, Mr. Cashman was President and Chief Executive Officer of SANUWAVE Health, a regenerative medicine company focused on the development and commercialization of Extracorporeal Shock Wave Technology for chronic wound care, orthopaedic, cardiovascular and plastic surgery. Before joining SANUWAVE, he served as President of Therapeutic Surfaces for Kinetic Concepts, Inc. (KCI), a worldwide leader in advanced wound healing products. Prior to that, Mr. Cashman was Chief Executive Officer for Snowden Pencer, a manufacturer of minimally invasive devices and specialty surgical instrumentation. He successfully led a management buyout of Snowden Pencer from Genzyme in 2001, and the business was sold in 2004 to Cardinal Health. Mr. Cashman also held various sales, marketing and general management positions within divisions of Genzyme Biosurgery and Deknatel. Following his graduation from the Naval Academy, Mr. Cashman served on the USS Trepang, a fast attack nuclear submarine.
Mr. Cashman is also an Industry Fellow and Advisor to the Georgia Research Alliance (GRA) where he guides and assists GRA Venture supported University research and early stage companies to aid in building successful businesses in the medical sciences and technology fields. He holds an MBA from Northwestern University's Kellogg Graduate School of Management, and is a graduate of the United States Naval Academy, where he received a Bachelor's of Science in Economics.
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 300,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Source: MiMedx Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.